|
Title
|
Contents
|
Source
|
|
Upjohn literature search
|
Literature search identifying later studies
|
Upjohn
|
|
Literature provided by Public Citizen
|
All cited references, including Kales (1996), A Reassessment of Triazolam and Conflicting Scientific Expertise in British and American Medicines Control
|
Public Citizen
|
|
International data
|
|
Canadian product monograph for Halcion
|
|
Canada
|
|
Evaluations of Medications for Insomnia in Canada (EMIC)
|
|
Upjohn
|
|
Medicines Control Agency letter
|
Letter from the Licensing Authority to Upjohn, 1992
|
Public Citizen
|
|
Report of the Committee on Proprietary Medicinal Products
|
|
Upjohn
|
|
Report of the Committee on the Safety of Medicines
|
|
Public Citizen
|
|
UK Panel Report
|
Report of the Panel of Persons Appointed
|
United Kingdom
|
|
VAMP Information
|
Information on the General Practice Research Database (previously known as the Value Added Medical Practice [VAMP] Database)
|
Upjohn
|
|
Premarketing clinical trial data (from the New Drug Application)
|
|
Preapproval reviews
|
|
FDA
|
|
Premarketing clinical trials
|
|
FDA
|
|
Report of the database remake
|
|
FDA
|
